Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

MOMENTOUS NEWS — Potential New Lupus Treatment Effectively Reduced Disease Activity in Phase III Trial

NEW YORK, NY. August 29 — The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies […]

New Study Shows Benlysta Alters B Cells in People with Lupus

August 21, 2019 Newly published research found that belimumab (Benlysta®) effectively reduced the number of B cells, a type of white blood cell that makes antibodies.  According to the prescribing information, belimumab is “a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody positive, systemic lupus […]

New Study Shows Active Epstein-Barr Virus Increases Chance for Lupus in At-Risk People

August 13, 2019 New research results showed that active Epstein-Barr virus increases the risk for lupus among relatives of people who already have lupus. Epstein-Barr virus is one of the most common human viruses. After the first infection, the virus becomes inactive in your body and can reactivate at any time. Scientists have known that […]

PALS Clinical Trial Program Opens at Five Universities

August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […]

New Trial of Promising Lupus Treatment RSLV-132 Has Finished Enrolling Patients

July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132.  Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […]

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […]

Lupus Research Alliance and Lupus Therapeutics – Leading Voices in Trial Diversity

June 25, 2019 Caroline Donovan, Manager of Patient Engagement at Lupus Research Alliance (LRA) affiliate Lupus Therapeutics (LT) took part in a panel discussion at the DIA 2019 (Drug Information Association) annual meeting, aimed at finding ways to make sure that diverse groups of patients can make informed choices about joining a clinical trial. Ms. […]

NIH Work Co-Supported by LRA May Simplify Lupus Nephritis Monitoring

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […]

Cyclosporine Worked Faster than Mycophenolate Mofetil or Azathioprine for Lupus Nephritis

June 12, 2019 A study presented at EULAR showed that ongoing maintenance therapy with the immunosuppressive drug cyclosporine helped lower proteinuria — the level of protein in urine — faster than other immunosuppressive drugs mycophenolate mofetil or azathioprine in people with lupus nephritis.  The three were comparable in their ability to cause remission of Lupus […]

Gut Bacteria May Cause Antiphospholipid Syndrome, LRA-Funded Study Shows

June 18, 2019 A common type of bacteria living in the gut may spark a common lupus complication called antiphospholipid syndrome, a study partly funded by the Lupus Research Alliance shows. Antiphospholipid syndrome can lead to blood clots and miscarriages.  Led by Dr. Martin Alexander Kriegel of Yale School of Medicine, the research may also […]

KZR-616 Shows Promise According to Results Reported at EULAR

Kezar Life Sciences announced positive results from the MISSION Phase 1 study testing the investigational KZR-616 as a treatment for lupus.  The presentation was at the European League Against Rheumatism (EULAR) 2019 annual meeting. The primary goal of the study was to assess if KZR-616 is safe and well tolerated. The study also looked at […]

Stelara® Effective Over One Year and Reduces Severe Flares

Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over one year. Both highlight the benefit of ustekinumab on disease activity and the rate of severe flares. Ustekinumab reduced the rate of severe flares four times as much as placebo by week 24. The rate of […]

Rituximab Effective for Maintenance Lupus Treatment Shows Study

June 13, 2019 A study published in Arthritis & Rheumatology found that rituximab was helpful as a maintenance therapy for tough-to-treat lupus patients. Maintenance treatment refers to one designed to help a main treatment work.  Rituximab is approved by the U.S. Food and Drug Administration for two types of cancer. It is sold by the […]

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […]

Results Presented at EULAR Find Investigational Lupus Treatment NKTR-358 Safe

June 13, 2019 New results from a clinical study with healthy volunteers found the investigational compound NKTR-358 safe and well-tolerated, providing support for testing it as a treatment for autoimmune diseases such as lupus. Researchers have known that impaired production of interleukin-2 (IL-2) and dysfunctioning regulatory T cells called Tregs are key to breaking down […]

Lupus Research Alliance Pleased to Share Positive News about Potential Drug for Lupus Nephritis

NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus.  Genentech, a member of the Roche Group, reported that at one year their […]

Lupus Research Alliance Congratulates Dr. Betty Diamond for Well-Deserved Recognition by AAI

May 20, 2019 The LRA applauds Betty Diamond, MD for being named a Distinguished Fellow by the American Association of Immunologists (AAI) at their 2019 annual meeting. A top expert in lupus and autoimmune disease, Dr. Diamond co-chairs a committee of our affiliate Lupus Therapeutics Lupus Clinical Investigators Network (LuCIN) that evaluates drugs to be […]

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […]

The Numbers Add Up to 20 Years of Extraordinary Progress

May 1, 2019 The Lupus Research Alliance is honored to serve the lupus community as the global leader in lupus research, both in the resources we deploy and the results we deliver.  Collectively we have invested more than $200 million in over 500 grants selected by a multi-level peer review process led by world-class luminaries […]

Gene Changes Key to Successful Pregnancy in Lupus

April 29, 2019 Pregnant women with lupus are more likely to suffer complications than those who don’t. Lupus Research Alliance Scientific Advisory Board members Dr. Virginia Pascual, Professor at Weill Cornell Medicine; and Dr. Jane Salmon, Collette Kean Research Professor  at Hospital for Special Surgery, and their colleagues asked if testing the blood, of pregnant […]

Test Available to Address Blood Clots in Lupus

April 24, 2019 The pharmaceutical company Exagen, Inc. announced study results showing that a component of their AVISE SLE Monitor test, the biomarker PC4d, can assess risk for thrombosis – a blood clot in the blood vessels. Study author Dr. Michelle Petri, Professor of Medicine at the Johns Hopkins University School of Medicine and Director […]

Severe Mental Illness in Lupus Patients is Rare, Treatable, and Usually Short-Lived

April 18, 2019 A large international study has probed the causes of lupus-related psychosis—a serious condition marked by delusions and hallucinations. Dr. John Hanly and his co-authors at research centers across several continents found that lupus psychosis (LP) is quite rare, affecting only 1.5 percent of people with lupus. They also observed that the condition […]

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […]

New Treatment Approaches Supported by LRA Were Highlighted at LUPUS 2019

April 11, 2019 The bacteria that cause urinary tract infections may trigger lupus flares, a former Alzheimer’s disease therapy has shown promising results in research models—these are just some of the findings presented by Lupus Research Alliance-funded scientists at the 13th International Congress on Systematic Lupus Erythematosus (LUPUS 2019), held in San Francisco. Here are […]

LRA Funding Helps Identify Uncontrolled Blood Pressure as Particular Risk in Lupus

New results partially funded by the Lupus Research Alliance found that people with systemic lupus erythematosus have almost double the risk for a dangerous condition, resistant hypertension (RHTN) than those without the disease. RHTN is defined as blood pressure that either remains high despite treatment with three anti-hypertensive medications or is controlled only with four […]

End of content

No more pages to load